SGLT2抑制剂依帕列净的药理作用与临床评价

Pharmacological and clinical evaluation of empagliflozin in the treatment of type 2 diabetes

依帕列净是一种钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,适用于2型糖尿病患者对血糖的控制,于2014年8月1日经美国食品药品监督管理局(FDA)批准上市。其一般耐受性良好,最常见的不良反应为尿道感染和生殖器感染。本文通过对依帕列净进行文献检索,对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。

Empagliflozin is a new sodium-glucose co-transporter 2 （SGLT2） inhibitor indicated to be the first-line treatment for patients with type 2 diabetes. Empagliflozin was approved by FDA on August 1 , 20t4. It is generally well tolerated. The most common adverse reactions are urinary tract infections and genital infections. A literature search was conducted with the key word empagliflozin. The pharmacology, pharmacokinetics, clinical re- search, safety, dosage, and drug interactions were reviewed in this paper.